Management of Calcium-Phosphate Product in ESRD

Target Parameters and Mortality Risk

The American College of Cardiology recommends maintaining serum phosphorus below 6.5 mg/dL and calcium-phosphorus product below 55 mg²/dL² to minimize vascular calcification and cardiovascular mortality risk 1
Target serum calcium toward the lower end of normal range (8.4-9.5 mg/dL) to reduce soft tissue and vascular calcification risk 1
Maintain calcium-phosphorus product below 55 mg²/dL² as the safety threshold 1

Stop all calcium-based phosphate binders immediately if corrected serum calcium exceeds 10.2 mg/dL (2.54 mmol/L) 1
Use non-calcium, non-aluminum, non-magnesium phosphate binders as first-line therapy for hyperphosphatemia 1
Limit total elemental calcium intake from all sources to maximum 2,000 mg/day, with calcium from binders alone not exceeding 1,500 mg/day 1

For patients on intensive hemodialysis who discontinue calcium-based binders, use dialysate calcium concentration of 1.5 mmol/L or higher to prevent negative calcium balance 2, 3
Higher dialysate calcium (1.5-1.75 mmol/L) prevents bone mineral density loss and controls PTH elevation without documented worsening of vascular calcification in current literature 2, 3

Measure corrected total calcium and phosphorus at least every 3 months during stable treatment 1
During acute management or dose adjustments, monitor weekly to biweekly until parameters stabilize 1
Check intact PTH levels—if PTH is below 150 pg/mL on two consecutive measurements, calcium-based binders are absolutely contraindicated 1

Never continue calcium-based phosphate binders when serum calcium exceeds 10.2 mg/dL—this directly worsens vascular calcification and soft tissue deposits 1
Avoid aluminum-based binders except as short-term rescue therapy (≤4 weeks maximum, one course only) for severe refractory hyperphosphatemia 1
Do not ignore rising alkaline phosphatase and PTH levels in dialysis patients, as these indicate need for dialysate calcium adjustment 3, 4
Recognize that positive calcium balance from liberal calcium exposure causes harm across all CKD stages, including progression of coronary and aortic calcification 1